Industry Survey: FDA Regs Driving VC Investment Overseas
This article was originally published in The Gray Sheet
Executive SummaryAn estimated 42% of U.S. venture capital firms will reduce their medical device sector investments over the next three years due to a perception that FDA regulations are cost-prohibitive, arbitrary and cumbersome, according to the latest industry survey.
You may also be interested in...
A survey of Minnesota device executives released last week closely aligns with previous industry polls, but the timing is notable: it comes just as Congress is completing passage of a user fee reauthorization bill championed by national device groups.